BACKGROUND: The Edmonton Symptom Assessment System (ESAS) is developed for daily symptom assessment. Validation studies tested a variety of languages and patients. The purpose was to carry out a comprehensive examination of the psychometric properties of the ESAS through validation of the version in Spanish advanced cancer patients. METHOD: A reverse translation method was used to translate the ESAS. Previous studies find appropriate Spanish terms to explore, with verbal scales, fatigue, depression and anxiety. Psychometric aspects evaluated were reliability, validity, responsiveness and utility. RESULTS: 171 advanced cancer patients participated. Internal consistency with Cronbach's Alpha was 0.75. In test-retest (0-6h), Spearma's correlation was between 0.65 and 0.94. Factor analysis found 3 central domains: 'soft' and 'hard physical' and 'emotional'. Concurrent validity with the Rotterdam Symptom Check List (RSCL) found good correlation in physical symptoms (Kappa until 0.66) but weak correlation in emotional symptoms (Kappa 0.35). Discriminant validity (Spearman) found significant differences (p<0.001) classifying by Karnofsky. ESAS discriminate between inpatients and outpatients (Mann-Whitney, p<0.001). Responsiveness was tested with ESAS at 0-48 h (Wilcoxon test, p<0.05). Average time to complete the instrument was 5.5 min. CONCLUSION: ESAS is a valid, reliable, responsive and feasible instrument with adequate psychometric properties when tested on Spanish advanced cancer patients.
BACKGROUND: The Edmonton Symptom Assessment System (ESAS) is developed for daily symptom assessment. Validation studies tested a variety of languages and patients. The purpose was to carry out a comprehensive examination of the psychometric properties of the ESAS through validation of the version in Spanish advanced cancerpatients. METHOD: A reverse translation method was used to translate the ESAS. Previous studies find appropriate Spanish terms to explore, with verbal scales, fatigue, depression and anxiety. Psychometric aspects evaluated were reliability, validity, responsiveness and utility. RESULTS: 171 advanced cancerpatients participated. Internal consistency with Cronbach's Alpha was 0.75. In test-retest (0-6h), Spearma's correlation was between 0.65 and 0.94. Factor analysis found 3 central domains: 'soft' and 'hard physical' and 'emotional'. Concurrent validity with the Rotterdam Symptom Check List (RSCL) found good correlation in physical symptoms (Kappa until 0.66) but weak correlation in emotional symptoms (Kappa 0.35). Discriminant validity (Spearman) found significant differences (p<0.001) classifying by Karnofsky. ESAS discriminate between inpatients and outpatients (Mann-Whitney, p<0.001). Responsiveness was tested with ESAS at 0-48 h (Wilcoxon test, p<0.05). Average time to complete the instrument was 5.5 min. CONCLUSION: ESAS is a valid, reliable, responsive and feasible instrument with adequate psychometric properties when tested on Spanish advanced cancerpatients.
Authors: Omar Shamieh; Odai Khamash; Mustafa Khraisat; Omar Jbouri; Mohammad Awni; Abdulrahman Al-Hawamdeh; Ghadeer Arja; Sawsan Ajarmeh; Dalia Al-Rimawi; David Hui Journal: Support Care Cancer Date: 2016-09-07 Impact factor: 3.603
Authors: Wadih Rhondali; Sriram Yennurajalingam; Gary Chisholm; Jeanette Ferrer; Sun Hyun Kim; Jung Hun Kang; Marilene Filbet; Eduardo Bruera Journal: Support Care Cancer Date: 2013-04-16 Impact factor: 3.603
Authors: David Hui; Minjeong Park; Omar Shamieh; Carlos Eduardo Paiva; Pedro Emilio Perez-Cruz; Mary Ann Muckaden; Eduardo Bruera Journal: Cancer Date: 2016-03-11 Impact factor: 6.860
Authors: Sriram Yennurajalingam; Jie S Willey; J Lynn Palmer; Julio Allo; Egidio Del Fabbro; Evan N Cohen; Sanda Tin; James M Reuben; Eduardo Bruera Journal: J Palliat Med Date: 2012-08-10 Impact factor: 2.947